As a company listed in Hong Kong, WuXi Biologics is the world's leading integrated empowerment platform for biopharmaceutical R&D and production, dedicated to accelerating global biopharmaceutical R&D process, reducing R&D costs and benefiting patients.
WuXi Biologics has set up R&D and production bases in Shanghai, Wuxi and Suzhou. The total number of employees exceeds 4,000, among which more than 300 are well-educated and experienced returnee scientists. Supported by such a talent team, WuXi Biologics has become a globally competitive open and integrated empowerment platform for biopharmaceutical capabilities and technologies in just a few years, and it was successfully listed in Hong Kong in June 2017.
WuXi Biologics has a diverse and high-quality client base, with over 200 domestic and foreign biopharmaceutical companies, including 22 of China's top 50 pharmaceutical companies; its partners include 13 of the world's top 20 pharmaceutical companies. The company has provided all-round end-to-end R&D services to biopharmaceutical and biotechnology companies across the world for many years and it enjoys an excellent reputation in the industry.
WuXi Biologics’ products mainly include monoclonal antibodies, bispecific antibodies, FC fusion proteins, ADC therapy, recombinant proteins and so on. According to the company’s 2017 Annual Report, its revenue in 2017 increased by 63.7%, hitting a record high, and its net profit increased by 85.1%. Since 2017, the 30,000-liter cGMP biologics commercial production facility (MFG2) using a disposable bioreactor and the 7000-liter cGMP facility (MFG3) at the Shanghai base have been put into operation successively. Wuxi Biologics is also building four new cGMP production facilities. These facilities will be expanded to further advance the company’s strategy of “expanding businesses in line with the development phase of drug molecules” to keep expanding its client base, maintaining strong growth momentum and consolidating its leading position in the industry in the future.
In March 2018, Trogarzo, developed by TaiMed Biologics and supported by WuXi Biologics, was approved to list by FDA of the US. This is the first sterile biological product produced in China and approved by the FDA to enter the US market. WuXi Biologics is the only biopharmaceutical company in China that has passed the GMP certification of FDA of the US, demonstrating its highest quality commitment to global biopharmaceutical clients.
As of June 30, 2018, 187 comprehensive projects have been developed on WuXi Biologics’ platform, of which 98 are in pre-clinical research phase, 78 are in early clinical phase (Phase I, Phase II), 10 are in late clinical phase (Phase III) and 1 is in commercial production phase. It is estimated that by 2021, the company's biopharmaceutical production bases in China, Ireland, Singapore and the United States will have a combined capacity of approximately 220,000 liters. That will ensure the company to provide customers with biopharmaceuticals meeting global quality standards through a robust global supply chain network.
In the future, WuXi Biologics will continue to cultivate and attract talents at home and abroad, develop global leading technologies, accelerate global biopharmaceutical R&D processes, and expand commercial production capabilities, so as to create a broader and deeper integrated service platform for biopharmaceutical R&D technologies and capabilities.